Strahlentherapie und Onkologie最新文献

{"title":"Patient preferences and travel burden before radiotherapy for primary cutaneous lymphoma: baseline results from the S-MISR registry.","authors":"David Rene Steike, Khaled Elsayad, Isabel Falke, Christian Kandler, Hans Theodor Eich","doi":"10.1007/s00066-026-02615-z","DOIUrl":"https://doi.org/10.1007/s00066-026-02615-z","url":null,"abstract":"<p><strong>Purpose: </strong>Patients with primary cutaneous lymphoma may have substantial impairments in health-related quality of life (HRQoL) and may require referral to specialized radiation oncology centers. The current exploratory baseline analysis assessed patient preferences for quality of life (QoL) versus length of life (LoL), travel distance, and baseline HRQoL before radiotherapy.</p><p><strong>Methods: </strong>Of 130 screened patients, 82 patients with primary cutaneous lymphoma referred for radiotherapy were enrolled in the prospective S‑MISR registry between September 2019 and August 2024. Their QoL-versus-LoL preferences were assessed using the Quality-Quantity Questionnaire. Baseline HRQoL was evaluated using Skindex-29 and EORTC QLQ-C30. Travel distance to the treating radiation oncology department was analyzed overall and by lymphoma subtype.</p><p><strong>Results: </strong>Median age was 63 years (range 34-92), and 59 patients (72%) had advanced-stage disease. Fifty-six patients (68%) had mycosis fungoides (MF), 13 (16%) had Sézary syndrome (SS), and 13 (16%) had other primary cutaneous lymphomas. Overall, 31 patients (38%) prioritized QoL, 21 (25%) prioritized LoL, and 30 (37%) rated both equally. Median travel distance was longest for Sézary syndrome (201 km), followed by mycosis fungoides (114 km) and non-MF/SS lymphomas (65 km). Older age and longer travel distance emerged as potential factors associated with QoL preference. Baseline Skindex-29 scores indicated greater HRQoL impairment in MF and SS than in non-MF/SS lymphomas.</p><p><strong>Conclusion: </strong>Patient preferences regarding QoL versus LoL vary considerably before radiotherapy. Travel burden may be an important patient-centered factor for treatment planning, shared decision-making, and future prospective radiotherapy studies.</p>","PeriodicalId":21998,"journal":{"name":"Strahlentherapie und Onkologie","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2026-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149184512","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative toxicity and efficacy of consolidative thoracic radiotherapy after first-line chemoimmunotherapy in extensive-stage small-cell lung cancer: real-world retrospective cohort study.","authors":"Bing Bai, Yuhua Jiang, Hanqing Meng, Lei Song, Kai Wu, Jun Wei, Na Si","doi":"10.1007/s00066-026-02583-4","DOIUrl":"https://doi.org/10.1007/s00066-026-02583-4","url":null,"abstract":"<p><strong>Background: </strong>First-line chemoimmunotherapy (CT-IT) is the standard treatment for extensive-stage small-cell lung cancer (ES-SCLC), while consolidative thoracic radiotherapy (cTRT) may improve local control and survival. This study evaluated the efficacy and safety of cTRT after first-line CT-IT in patients with ES-SCLC in a real-world setting.</p><p><strong>Methods: </strong>This retrospective cohort study included 199 patients with ES-SCLC who received first-line CT-IT. Patients were divided into a CT-IT + cTRT group (n = 97) and a CT-IT alone group (n = 102). Survival outcomes included progression-free survival (PFS) and overall survival (OS). Treatment-related adverse events were assessed.</p><p><strong>Results: </strong>The two groups were generally comparable at baseline, although the CT-IT + cTRT group had fewer brain metastases and more favorable response-related features after induction treatment. Median PFS and OS were significantly longer in the CT-IT + cTRT group (both P < 0.001). cTRT (P < 0.001) and a longer duration of maintenance immunotherapy (P = 0.031) were independently associated with a better PFS. For OS, cTRT was associated with better survival status (P = 0.003) and liver metastasis with poorer survival status (P = 0.015). Regarding safety, grade 1-2 dermatitis and gastrointestinal toxicity were more frequent in the CT-IT + cTRT group, whereas rates of pneumonitis, esophagitis, immune-related adverse events, and grade 3-4 toxicities were comparable between groups.</p><p><strong>Conclusion: </strong>In this real-world retrospective cohort, the addition of cTRT to first-line CT-IT was associated with significantly improved PFS and OS in patients with ES-SCLC, without an apparent increase in severe treatment-related toxicity. Prospective studies are warranted to confirm these findings and refine patient selection for cTRT.</p>","PeriodicalId":21998,"journal":{"name":"Strahlentherapie und Onkologie","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2026-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149169845","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of PET-detected nodal upstaging and planning target volume expansion in esophageal cancer radiotherapy planning.","authors":"Sanyamita Jain, Brijesh Maheshwari, Akash R Bellige, Sarthak Tandon, Apoorva Nayak, Abhishek Bhadri, Sachin Pandey, Parveen Ahlawat, Munish Gairola","doi":"10.1007/s00066-026-02614-0","DOIUrl":"https://doi.org/10.1007/s00066-026-02614-0","url":null,"abstract":"<p><strong>Background: </strong>While 18F-fluorodeoxyglucose positron emission tomography (FDG-PET/CT) is known to influence staging, its quantitative impact on clinically meaningful target volume expansion remains incompletely characterized. We evaluated whether PET-detected nodal upstaging is associated with significant planning target volume (PTV) expansion.</p><p><strong>Methods: </strong>Fifty consecutive eligible patients with esophageal cancer undergoing computed tomography (CT)- and PET-based radiotherapy planning between January 2018 and January 2022 were retrospectively analyzed, with no predefined target sample size. Clinically significant PTV expansion was predefined as a > 10% increase from CT-based to PET-based planning. Associations between PET-detected nodal upstaging and PTV expansion were evaluated using Fisher's exact test, logistic regression, receiver operating characteristic (ROC) analysis, and nonparametric testing. Given the limited number of events, a parsimonious multivariable model and threshold sensitivity analyses were additionally performed.</p><p><strong>Results: </strong>Patients with nodal upstaging had a significantly higher risk of > 10% PTV expansion (48.0% vs. 16.7%; absolute risk difference 31.3%, 95% CI 6.7-55.9%; p = 0.032). The median percent PTV change was significantly higher in patients with nodal upstaging (9.49% vs. 0.31%; Wilcoxon p < 0.001). In a parsimonious multivariable model adjusting for tumor length, nodal upstaging remained independently associated with clinically significant PTV expansion (odds ratio (OR) 4.38, 95% confidence interval (CI) 1.12-17.10; p = 0.033). Model discrimination was acceptable (area under the curve (AUC) 0.7254), with stable performance on bootstrap internal validation (bootstrap mean AUC 0.733). Sensitivity analyses using alternative expansion thresholds (> 5%, > 10%, and > 15%) demonstrated directionally consistent associations. Patients meeting the PTV expansion threshold also demonstrated significantly greater increases in lung dose-volume burden (mean lung dose, and lung volumes receiving 5 Gy and 20 Gy; all p < 0.001) in paired dosimetric comparison, supporting the clinical relevance of this threshold.</p><p><strong>Conclusion: </strong>During esophageal cancer radiotherapy planning, PET-detected nodal upstaging was independently associated with clinically meaningful target volume expansion. The association was consistent across alternative expansion thresholds and in bootstrap internal validation, and a paired lung dose-volume comparison indicated that the expansion threshold corresponds to a measurable increase in lung dose burden.</p>","PeriodicalId":21998,"journal":{"name":"Strahlentherapie und Onkologie","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2026-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149164905","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Increased number of chemotherapy cycles during radiochemotherapy improves overall survival without increasing toxicity in locally advanced non-small cell lung cancer patients.","authors":"Anna Simbirova, Steffen Löck, Steffen Appold, Alex Zwanenburg, Dirk Koschel, Olaf Holotiuk, Rebecca Bütof, Esther G C Troost","doi":"10.1007/s00066-026-02612-2","DOIUrl":"https://doi.org/10.1007/s00066-026-02612-2","url":null,"abstract":"<p><strong>Purpose: </strong>Radiochemotherapy (RCHT) followed by immunotherapy is the standard of care for unresectable, locally advanced non-small cell lung cancer (LA-NSCLC) patients. However, the impact of chemotherapy cycles and consolidation durvalumab on overall survival and toxicity remains uncertain in a real-life cohort.</p><p><strong>Methods: </strong>We retrospectively analyzed 90 patients with stage IIB-IIIC LA-NSCLC treated with definitive RCHT (56-66 Gy, using weekly carboplatin/paclitaxel). Fifty of these patients received consolidation durvalumab. Chemotherapy cycles were analyzed as a stratified variable (1-4 vs. 5-7 cycles) and as a continuous predictor. Patients were also stratified by durvalumab administration. Early and late toxicities grade ≥ 2 were evaluated according to CTCAE v5.0. Overall survival (OS) was assessed via Kaplan-Meier analysis, log-rank test, Cox regression.</p><p><strong>Results: </strong>Median follow-up was 33.5 months. Patients receiving 5-7 chemotherapy cycles had significantly longer OS than those with 1-4 cycles (p = 0.048). This finding was confirmed when treating the cycle number as a continuous variable (HR = 0.75 per additional cycle; p = 0.017). Durvalumab showed a trend towards improved OS (p = 0.075). No significant increase in early or late toxicity was observed with more chemotherapy cycles. Amongst the toxicity parameters, early grade ≥ 2 anemia (27.8%) was associated with worse OS (p = 0.006).</p><p><strong>Conclusion: </strong>Receipt of 5-7 chemotherapy cycles during RCHT was associated with improved OS without an increase in grade ≥ 2 toxicity. Early anemia emerged as a key prognostic marker and was closely linked to chemotherapy de-escalation. In addition, OS estimates in durvalumab-treated patients were broadly consistent with outcomes reported in pivotal post-CRT immunotherapy trials.</p>","PeriodicalId":21998,"journal":{"name":"Strahlentherapie und Onkologie","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2026-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149137557","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Author's reply to Rao et al.-\"DEGRO practical guidelines: radiotherapy of breast cancer-regional nodal irradiation\".","authors":"Kai Borm, Marciana Nona Duma, David Krug, Juliane Hörner-Rieber","doi":"10.1007/s00066-026-02610-4","DOIUrl":"https://doi.org/10.1007/s00066-026-02610-4","url":null,"abstract":"","PeriodicalId":21998,"journal":{"name":"Strahlentherapie und Onkologie","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2026-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149137596","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tightening the gradient: ten years of dosimetric refinement in head and neck reirradiation.","authors":"Sandeep Singh, Supratik Sen, Abhay Kumar Singh, Dipesh, Manindra Bhushan, Kothanda Raman Samuvel, Soniya Pal, Sarthak Tandon, Akash R Bellige, Munish Gairola, Mahipal","doi":"10.1007/s00066-026-02613-1","DOIUrl":"https://doi.org/10.1007/s00066-026-02613-1","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to quantify changes in plan quality for head and neck reirradiation (reRT) on a constant C‑arm platform.</p><p><strong>Methods: </strong>This retrospective study included 775 patients treated on a TrueBeam STx (Varian Medical Systems, Palo Alto, USA) between 2015 and 2025. Delivery transitioned from fixed-field IMRT during 2015-2019 to VMAT during 2020-2025. Planning was performed in Eclipse, with one upgrade from version 11.0.31 to 15.6.06. Endpoints included PTV D95, D98, D50, D2; different gradient indices; and doses to the spinal cord, brainstem, carotids, mandible, oral cavity, and DARS. Year-wise differences were tested using ANOVA with Bonferroni-adjusted pairwise comparisons and nonparametric sensitivity analyses. Linear models included calendar year and the log-transformed PTV volume.</p><p><strong>Results: </strong>Mean PTV D95 increased from 96.4 ± 0.5% to 99.6 ± 0.2%, while D2 decreased from 108.5 ± 1.6% to 104.0 ± 0.1%. Gradient indices decreased over the study period, indicating reduced dose spillage and steeper dose fall-off. Spinal cord and brainstem doses also declined substantially, with additional reductions in oral cavity and DARS doses. All four primary target endpoints showed significant year effects after multiplicity adjustment and nonparametric sensitivity testing. The PTV volume decreased from 700.2 ± 16.7 cc to 250.4 ± 14.7 cc, representing an approximately 64% reduction, and likely contributed to the observed improvements in gradient indices and OAR sparing. Temporal associations persisted after adjustment for the log-transformed PTV volume.</p><p><strong>Conclusion: </strong>Dosimetric outcomes improved over the study period, but these changes coincided with reduced target volume, treatment technique transition, TPS upgrade, and workflow maturation. The findings should be interpreted as multifactorial rather than as evidence of an isolated technological effect.</p>","PeriodicalId":21998,"journal":{"name":"Strahlentherapie und Onkologie","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149128511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Application of delta radiomics based on cone-beam computed tomography in predicting radiotherapy efficacy for nasopharyngeal carcinoma.","authors":"Zhongfan Liao, Hongke Yin, Dashuang Luo, Jiaxing Xu, Xiaozhou Zeng, Xiaoyan Tang, Fasheng Huang, Xuhui Zhang","doi":"10.1007/s00066-026-02551-y","DOIUrl":"10.1007/s00066-026-02551-y","url":null,"abstract":"<p><strong>Purpose: </strong>To investigate the value of cone-beam computed tomography (CBCT)-based delta radiomics for predicting short-term radiotherapy (RT) response in nasopharyngeal carcinoma (NPC).</p><p><strong>Methods: </strong>A total of 132 pathologically confirmed NPC patients receiving RT were retrospectively enrolled. Serial CBCT images during weeks 1-4 were collected. Patients were grouped by therapeutic response and randomly divided into training and test sets (7:3). Radiomic features from fractional CBCTs were extracted via Pyradiomics. Temporal delta-radiomic features were derived from interfraction differences. After applying feature normalization and dimensionality reduction, optimal features were selected using analysis of variance (ANOVA), recursive feature elimination, relevant features, and Kruskal-Wallis tests. Ten classifiers, including logistic regression (LR), were trained with 5‑fold cross-validation strategy. Predictive performance was evaluated by receiver operating characteristic (ROC) curves, decision curve analysis (DCA), and the DeLong's test.</p><p><strong>Results: </strong>The LR model based on the CBCT_1st-3rd temporal interval achieved the optimal predictive performance (balanced accuracy 0.73, area under the curve [AUC] 0.74, sensitivity 0.64, specificity 0.81) in the cross-validation set. DeLong's tests revealed no statistically significant differences (P > 0.05) in AUC values within the cross-validation set between the CBCT_1st-3rd model and models based on CBCT_1st-4th or CBCT_2nd-4th intervals. DCA indicated that the LR model based on CBCT_1st-3rd temporal interval provided the highest net clinical benefit within threshold probabilities ranging from 0.2 to 0.4 and exceeding 0.65.</p><p><strong>Conclusion: </strong>The CBCT-based delta radiomics models can dynamically assess short-term RT response in NPC patients. This approach offers potential as an early-warning indicator during the RT course and provides a novel approach to guiding personalized precision radiotherapy for NPC.</p>","PeriodicalId":21998,"journal":{"name":"Strahlentherapie und Onkologie","volume":" ","pages":"1048-1059"},"PeriodicalIF":2.8,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148144779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radiotherapy and DNA damage response inhibitors modestly sensitize HNSCC to NK cell killing, with ATM inhibition more effective than ATR inhibition.","authors":"Leonie Steinsdörfer, Lilli Zülch, Anna Schäfer, Benjamin Frey, Stefanie Corradini, Rainer Fietkau, Udo S Gaipl, Tina Jost","doi":"10.1007/s00066-026-02522-3","DOIUrl":"10.1007/s00066-026-02522-3","url":null,"abstract":"<p><strong>Purpose: </strong>Human papillomavirus (HPV)-negative head and neck squamous cell carcinomas (HNSCC) remain challenging due to their reduced radiosensitivity. Targeting the DNA damage response (DDR) with kinase inhibitors may enhance tumor susceptibility to radiotherapy (RT). While RT is known to alter the immune phenotype of HNSCC cells, its impact on innate immune responses, particularly on natural killer (NK) cells, remains unclear. We therefore investigated how RT combined with ATM or ATR inhibition-key DDR kinases-affects NK cell-mediated killing and activation.</p><p><strong>Methods: </strong>The tumor cell lines HSC4 and Cal33 (both HPV-negative) and UM-SCC-47 and UD-SCC‑2 (both HPV-positive) were treated with the DDR inhibitors VE-822 (ATRi) and AZD0156 (ATMi) and hypofractionated RT (2 × 5 Gy). After co-cultivation with primary human NK cells, tumor cell death was measured using flow cytometry after 24 h. Further, NK cell activation markers and the supernatant of tumor cell-NK cell co-cultures were measured and the effect of immune checkpoint inhibitors (durvalumab, monalizumab) was additionally investigated.</p><p><strong>Results: </strong>Particularly the HPV-negative HSC4 cells pretreated with either ATMi or RT + ATMi showed significantly increased killing by NK cells. Reduced secretion of granulysin by NK cells was mainly found in the co-cultures of HPV-negative HNSCC treated with ATRi. Treatment with the immune checkpoint inhibitor durvalumab (anti-PD-L1) did not result in significant augmentation of NK cell-induced tumor cell killing in this setting. Conversely, treatment with monalizumab (anti-NKG2A) resulted in a modest increase.</p><p><strong>Conclusion: </strong>Natural killer cells showed only a limited contribution to the killing of HNSCC cells pretreated with RT or RT + DDRi. However, a subset of patients with head and neck tumors-such as those represented by the HSC4 model-might still benefit from combining RT with ATMi rather than ATRi to enhance NK cell-mediated tumor killing.</p>","PeriodicalId":21998,"journal":{"name":"Strahlentherapie und Onkologie","volume":" ","pages":"1071-1082"},"PeriodicalIF":2.8,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13597543/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147718161","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Head and neck NUT carcinoma-radiotherapy dose, chemotherapy choice, and outcomes: lessons from a 7-year complete remission.","authors":"Lara Schulz, Matthias Zähringer, Klaus-Henning Kahl, Nikolaos Balagiannis, Bertram Jehs, Johannes Doescher, Johannes Zenk, Georg Stüben, Maria Neu","doi":"10.1007/s00066-026-02552-x","DOIUrl":"10.1007/s00066-026-02552-x","url":null,"abstract":"<p><strong>Background: </strong>NUT carcinoma (NUTc) is a rare, aggressive squamous carcinoma defined by NUTM1 rearrangements. Outcomes in head and neck (H&N) disease are poor, and no uniform treatment standard exists; available evidence largely derives from case reports and small series.</p><p><strong>Methods: </strong>We performed a structured narrative review of H&N NUTc with an emphasis on radiotherapy (RT) dose concepts, chemotherapy regimens, and outcome signals.</p><p><strong>Results: </strong>Published evidence indicates poor overall survival, particularly in metastatic disease. Long-term remissions have been described in selected patients with non-metastatic disease treated with multimodal approaches combining surgery, multi-agent chemotherapy, and early integrated RT. Across reports, use of RT in first-line management and delivery of definitive-dose RT are repeatedly associated with better outcomes. Evidence for immune checkpoint inhibitors is limited to anecdotal single-patient reports.</p><p><strong>Case vignette: </strong>A 19-year-old man with locally advanced supraglottic NUTc and bilateral cervical nodal disease (M0) presented with dysphagia and otalgia. Following laser debulking and temporary tracheostomy, induction cisplatin/doxorubicin/ifosfamide led to a complete metabolic response in positron-emission tomography/computed tomography (PET/CT) after two cycles of chemotherapy. Definitive PET/CT-guided intensity-modulated (IM)RT/image-guided (IG)RT was delivered to 73.2 Gy using an accelerated twice-daily schedule (2.0 Gy to the planning target volume [PTV] in the morning and 1.6 Gy boost to the initial gross target volume [GTV] in the afternoon; ≥ 8-hour interval). Acute toxicity was grade 3 dermatitis and grade 2 mucositis (CTCAE v5.0). After RT, chemotherapy was continued as consolidation and completed with vincristine/doxorubicin/ifosfamide (six cycles) due to acute kidney injury. Complete remission is ongoing at > 7 years, with persistent xerostomia and dysgeusia.</p><p><strong>Conclusion: </strong>In selected non-metastatic H&N NUTc, durable control has been reported with timely systemic therapy plus curative-intent RT, often exceeding 50 Gy. This review summarizes dose concepts and case-based systemic regimens and provides a comparative table to support individualized treatment planning.</p>","PeriodicalId":21998,"journal":{"name":"Strahlentherapie und Onkologie","volume":" ","pages":"1083-1090"},"PeriodicalIF":2.8,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13597622/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148138901","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Stereotactic radiotherapy for primary renal cell carcinoma: new findings from the FASTRACK trials].","authors":"Maike Trommer, Jürgen Dunst","doi":"10.1007/s00066-026-02572-7","DOIUrl":"10.1007/s00066-026-02572-7","url":null,"abstract":"","PeriodicalId":21998,"journal":{"name":"Strahlentherapie und Onkologie","volume":" ","pages":"1091-1093"},"PeriodicalIF":2.8,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148437945","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}